Phase III, multicenter, open-label study of ribociclib compared to palbociclib in patients with hormone receptor-positive/HER2-negative/HER2-enriched advanced breast cancer – HARMONIA trial.
INDEPENDENT CLINICAL TRIAL
Clinical trial information
- Promoter: SOLTI
- Phase: III
- Execution start: 24/11/2021
- End of execution: 28/02/2028
- IP: VERONICA CONDE HERRERO